23165-44-8

Usage

Uses

Used in Pharmaceutical Industry:
4-N-Butylphenyl isothiocyanate is used as an anticancer agent for its potential to inhibit the growth of cancer cells and induce apoptosis in various cancer cell lines. Its application in this industry is driven by the need for novel and effective cancer treatments.
Used in Antimicrobial Development:
4-N-Butylphenyl isothiocyanate is used as a potential antimicrobial agent in the development of novel antibiotics. Its application in this field is due to its ability to combat drug-resistant bacteria and contribute to the discovery of new antimicrobial compounds.
Further studies are warranted to fully understand the therapeutic potential of 4-N-butylphenyl isothiocyanate in both the pharmaceutical and antimicrobial industries.

InChI:InChI=1/C11H13NS/c1-2-3-4-10-5-7-11(8-6-10)12-9-13/h5-8H,2-4H2,1H3

Upstream product

• 104-13-2 4-Butylaniline 
• 463-71-8 thiophosgene 

Downstream Products

• 102556-64-9 N-(4-butyl-phenyl)-N'-(4-pentyl-phenyl)-thiourea 
• 111412-46-5 4-(4-butyl-phenyl)-1-phenyl thiosemicarbazide 
• 905492-23-1 N₁,N₂-bis(4-butylphenyl)-1,2-hydrazinedicarbothioamide 
• 1434159-09-7 N²,N⁵-bis(4-butylphenyl)-1,3,4-thiadiazole-2,5-diamine 
• 693255-81-1 C₁₅H₂₂N₂OS 
• 1421761-41-2 C₃₀H₄₂N₄O₂S 
• 902637-62-1 1-allyl-3-(4-buthylphenyl)thiourea 

Relevant academic research and scientific papers

ISOTHIOCYNATES AND GLUCOSINOLATE COMPOUNDS AND ANTI-TUMOR COMPOSITIONS CONTAINING SAME

The present invention provides glucosinolate and isothiocyanate compounds and related methods for synthesizing these compounds and analogs. In certain embodiments, these glucosinolate and isothiocyanate compounds are useful and chemopreventive and or chemotherapeutic agents.

Synthesis and biological evaluation of arylthiourea derivatives with antitubercular activity

Tuberculosis (TB) is a contagious disease caused by Mycobacterium tuberculosis (M. tuberculosis), and remains one of the most life-threatening plagues for public health in the world. The emergence of drug resistant strains of TB and co-infection with HIV has further complicated TB treatment. Here, the synthesis and characterizaton of a series of compounds were described, and these were followed by evaluating for their antibacterial activity against M. tuberculosis. Several novel arylthiourea derivatives exhibited excellent activity (lowest MIC=0.09 μg/ml) against M. tuberculosis including drug resistant strains of M. tuberculosis. The results suggest that these compounds are promising candidates for new anti-TB agent development.

ISOTHIOCYANATES AND GLUCOSINOLATE COMPOUNDS AND ANTI-TUMOR COMPOSITIOS CONTAINING SAME

The present invention provides glucosinolate and isothiocyante compounds and related methods for synthesizing these compounds and analogs. In certain embodiments, these glucosinolate and isothiocyanate compounds are useful and chemopreventive and or chemotherapeutic agents.

Synthesis of mesoionic 4-(para-substituted phenyl-5-2,4-dichlorophenyl)-1, 3-4-thiadiazolium-2-aminides by direct cyclization via acylation of thiosemicarbazides

The synthesis of ten novel mesoionic 4-[para-substituted (H, CH 3, OCH3, NO2, Cl, Br, OH, t-C4H 9, C6H5, C4H9) phenyl-5-2,4-dichlorophenyl]-1,3-4-thiadiazolium-2-aminides, as hydrochlorides, are described. The synthesis strategy utilized the corresponding para-substituted isothiocyanates as starting materials to obtain the thiosemicarbazides through reaction with phenylhydrazine (61-98%), which were then submitted to acylation with 2,4-dichloro benzoyl chloride and direct cyclization to generate the desired substituted mesoionic compounds in good yields (ca. 80%). Copyright Taylor & Francis Group, LLC.